Brief: Tiziana Life Sciences Announces Results From Second Patient With Secondary Progressive Multiple Sclerosis Following Three Months Of Dosing With Intranasal Foralumab
08/06/2022 13:36
June 8 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE CLINICAL RESULTS
IN THE
SECOND PATIENT WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
(SPMS) FOLLOWING THREE MONTHS OF DOSING WITH INTRANASAL
FORALUMAB
* TIZIANA LIFE SCIENCES - TREATMENT WITH FORALUMAB WAS
WELL-TOLERATED AND IMPROVED CLINICAL AND PET IMAGING ANALYSES
* TIZIANA LIFE SCIENCES - 2ND PATIENT SHOWED CLINICAL
IMPROVEMENTS
IN PET IMAGING ANALYSIS, NEUROLOGIC EXAM, TIMED 25-FOOT WALK
TEST, AFTER 3 MONTHS OF TREATMENT
* TIZIANA LIFE SCIENCES LTD - U.S. FDA HAS NOW ALLOWED
TIZIANA TO
TREAT AN ADDITIONAL EIGHT SPMS PATIENTS
Source text for Eikon: ID:nGNX1rWkV3
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis